TNFRSF17 biallelic loss was also identified by scCNV-seq in a patient with triple-class refractory MM (MM-2) who relapsed 6 months after receiving anti-BCMA TCE therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.